Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zoledronic Acid
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenacy Announces Launch of Zoledronic Acid Injection, USP in the U.S. Market
Details : Zometa-Generic (zoledronic acid) works by inhibition of bone resorption. It is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma.
Product Name : Zometa-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Zoledronic Acid
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable